ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.

Seung Tae Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.